Loading…
Agenus Inc. is projected to rise to $3.50 by 2027, a +4% move from its current price of $3.35. AGEN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $3.22 | $3.35 | $3.48 | -0.02% |
| Jul 13 | $3.17 | $3.35 | $3.54 | -0.05% |
| Jul 14 | $3.13 | $3.35 | $3.58 | -0.07% |
| Jul 15 | $3.09 | $3.35 | $3.62 | -0.10% |
| Jul 16 | $3.06 | $3.35 | $3.65 | -0.12% |
| Jul 17 | $3.04 | $3.35 | $3.68 | -0.15% |
| Jul 18 | $3.01 | $3.34 | $3.71 | -0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.01 | $3.34 | $3.71 | -0.17% |
| Week 2 | $2.88 | $3.34 | $3.87 | -0.34% |
| Week 3 | $2.78 | $3.33 | $3.99 | -0.51% |
| Week 4 | $2.70 | $3.33 | $4.10 | -0.68% |
| Week 5 | $2.63 | $3.32 | $4.19 | -0.85% |
| Week 6 | $2.57 | $3.32 | $4.28 | -1.02% |
| Week 7 | $2.51 | $3.31 | $4.36 | -1.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Agenus Inc. is a clinical-stage biotechnology company that discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884.
The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc.
and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Agenus Inc. (AGEN) is currently priced at $3.41 with a market capitalization of $142M and is ranked 4066 by market cap.
The near-term technical picture shows a neutral stance with RSI14 at 60. The 50-day simple moving average stands at $3.42 and the 200-day simple moving average at $3.67, placing the price in proximity to the short-term trend lines.
The stock trades within a 30-day range of $2.58 to $4.51, with a key support at $2.88 and a resistance at $3.50.
Longer-term forecasts imply a bullish trajectory, with 2027 avg $3.66, 2028 avg $4.10, 2030 avg $6.40, 2040 avg $11.48, and 2050 avg $23.09. The implied ROIs by year include 7.3% in 2027, 20.2% in 2028, 33.3% in 2029, 87.7% in 2030, 103.3% in 2031, 89.7% in 2032, 121.3% in 2033, 113.4% in 2034, 103.8% in 2035, 236.6% in 2040, and 577% in 2050, with a bullish sentiment persisting through the horizon.
A major floor 21.7% below — a decisive break under it would weaken the trend.
The nearest floor, 14.0% below — buyers have tended to step in here.
The nearest ceiling, 4.5% above — a clean break opens room to run.
A major ceiling 44.2% above — clearing it would confirm fresh momentum.
Key AGEN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AGEN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.35 | Neutral | $3.32 | Buy |
| MA 10 | $3.29 | Buy | $3.28 | Buy |
| MA 20 | $3.18 | Buy | $3.25 | Buy |
| MA 50 | $3.35 | Sell | $3.34 | Buy |
| MA 100 | $3.49 | Sell | $3.46 | Sell |
| MA 200 | $3.64 | Sell | $3.70 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.82 | Neutral |
| Stoch RSI (14) | 73.53 | Neutral |
| CCI (20) | 63.24 | Neutral |
| Williams %R (14) | -24.19 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 9.12 | Buy |
| Bollinger %B (20,2) | 0.71 | Neutral |
| Stochastic %K (14) | 75.81 | Neutral |
| TRIX (15) | -0.17 | Sell |
| Awesome (5,34) | 0.13 | Buy |
| Ultimate (7,14,28) | 61.35 | Neutral |
| Momentum (10) | 0.47 | Buy |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 3.31 | Buy |
| ADX (14) | 11.61 | Neutral |
| ATR (14) | 0.12 | Info |
In the last 30 days, Agenus traded between $2.58 and $4.51, with RSI14 at 60 and overall sentiment listed as NEUTRAL. The price is sitting near the 50-day moving average of $3.42, with the 200-day moving average at $3.67, suggesting a cautious stance as the stock tests near-term levels. Support is identified at $2.88 and resistance at $3.50, framing a modestly constrained near-term range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.77 | $3.35 | $4.49 | 0% | Neutral | |
| $2.67 | $3.50 | $4.91 | +4% | Neutral | |
| $2.83 | $3.87 | $5.71 | +16% | Neutral | |
| $2.91 | $4.12 | $6.33 | +23% | Bullish | |
| $3.87 | $5.65 | $8.94 | +69% | Bullish | |
| $4.15 | $6.24 | $10.16 | +86% | Bullish | |
| $3.77 | $5.83 | $9.73 | +74% | Bullish | |
| $4.14 | $6.57 | $11.23 | +96% | Bullish | |
| $3.99 | $6.50 | $11.32 | +94% | Bullish | |
| $3.72 | $6.20 | $11.01 | +85% | Bullish | |
| $5.33 | $9.93 | $19.09 | +197% | Bullish | |
| $8.40 | $18.67 | $40.16 | +457% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.77 | $3.35 | $4.10 | +0.00% |
| August 2026 | $2.76 | $3.30 | $4.08 | -1.50% |
| September 2026 | $2.71 | $3.28 | $4.11 | -0.72% |
| October 2026 | $2.86 | $3.48 | $4.42 | +6.13% |
| November 2026 | $2.90 | $3.56 | $4.58 | +2.47% |
| December 2026 | $2.80 | $3.46 | $4.49 | -2.96% |
Click any year to see its month-by-month AGEN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect AGEN to range from $2.77 to $4.49 through 2026. The $3.35 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The AGEN price prediction for 2027 points to an average of $3.50 (low $2.67, high $4.91) — a potential gain of +4% on today's $3.35. A consolidation phase looks the most probable path here.
In 2028, AGEN is projected to trade between $2.83 and $5.71, averaging $3.87 — a potential gain of +16% from today's $3.35. That is up +11% on the projected 2027 average. Price action looks broadly range-bound.
Agenus Inc.'s 2029 outlook centres on $4.12, within a $2.91 to $6.33 range. That is up +7% on the projected 2028 average. That marks a +23% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, AGEN could reach as high as $8.94, with a base case around $5.65 and support toward $3.87 — roughly +69% from $3.35. Momentum favours further upside here.
Expect AGEN to range from $4.15 to $10.16 through 2031. The $6.24 average target implies a +86% move from current prices. That is up +10% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The AGEN price prediction for 2032 points to an average of $5.83 (low $3.77, high $9.73) — a potential gain of +74% on today's $3.35. Momentum favours further upside here.
In 2033, AGEN is projected to trade between $4.14 and $11.23, averaging $6.57 — a potential gain of +96% from today's $3.35. That is up +13% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Agenus Inc.'s 2034 outlook centres on $6.50, within a $3.99 to $11.32 range. That is -1% versus the projected 2033 average. That marks a +94% change versus current levels. Momentum favours further upside here.
By 2035, AGEN could reach as high as $11.01, with a base case around $6.20 and support toward $3.72 — roughly +85% from $3.35. Buyers look set to stay in control over this stretch.
Expect AGEN to range from $5.33 to $19.09 through 2040. The $9.93 average target implies a +197% move from current prices. That is up +60% on the projected 2035 average. Momentum favours further upside here.
The AGEN price prediction for 2050 points to an average of $18.67 (low $8.40, high $40.16) — a potential gain of +457% on today's $3.35. Buyers look set to stay in control over this stretch.
Investing $1,000 in AGEN today (≈ 298.507463 AGEN) could be worth
$5,572.8
+$4,572.8 (+457%) by 2050 · US Dollar
Based on the average projected AGEN price of $18.67 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AGENwould be worth at today's price.
$1,000 invested in AGEN on Jul 10, 2025 (≈ 168.918917 AGEN) would be worth
$565.88
-$434.12 (-43.4%) today · 0.57× · US Dollar
Based on a AGEN entry price of $5.92 vs. today's $3.35.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.49 | $959.89 | -4.0% |
| 1 month ago | $3.07 | $1,091.21 | +9.1% |
| 3 months ago | $3.96 | $845.96 | -15.4% |
| 6 months ago | $4.25 | $788.24 | -21.2% |
| 1 year ago | $5.92 | $565.88 | -43.4% |
| All time (5.0y) ago | $110.7 | $30.26 | -97.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AGEN forecast.
Our base-case forecast reaches $6.70 around 2040.
Implied market cap at $6.70: $279M
The multi-year forecast shows a bullish trajectory across the horizon. The 2026-2030 window projects an average price rising from $3.41 in 2026 to $6.40 by 2030, with a max of $10.36 and a min of $4.29 in 2030, implying an ROI of 87.7 and a bullish tilt to valuations. By 2040, the average price is forecast at $11.48 with a max of $22.76 and a min of $5.85, delivering an ROI of 236.6 and continuing bullish sentiment.
By 2050, the average is projected at $23.09 with a max of $51.48 and a min of $10.39, supported by the anticipated very high ROI of 577 and a sustained bullish outlook. These figures are estimates and not guarantees; actual results will depend on future developments and market conditions.
Tap a question to reveal the answer.
2030 Avg price $6.40, Min $4.29, Max $10.36, ROI 87.7, Sentiment BULLISH.
Forecasts show a bullish sentiment from 2028 onward, with 2028 Avg $4.10, 2029 $4.55, 2030 $6.40, 2040 $11.48, and 2050 $23.09. ROI figures rise to 20.2, 33.3, 87.7, 236.6, and 577, respectively. These are estimates and not guarantees.
Yes. The 2030 max is $10.36, with a min of $4.29 and an average of $6.40.
The 2050 max is $51.48, with an average of $23.09 and a min of $10.39.
Current price is $3.41 and market capitalization is $142M (rank 4066).
Agenus Inc. Community Discussion
0Share your Agenus Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.